GCA Savvian and Altium Sign Definitive Merger Agreement to Form GCA
GCA Savvian Corporation, a premier global investment bank (TSE: 2174), and Altium, a leading international mid-market financial advisory group, today announced that they have entered into a definitive merger agreement. This combination creates a leading independent international investment bank focused on growth companies with an extensive global network, cross-border capability and track record of industry-shaping transactions. GCA will operate under the names GCA Altium in Europe and GCA in the United States and Asia.
Upon the completion of the transaction, GCA will be a leading global pure play advisory business with a focus on growth companies and the 7th largest listed M&A advisory firm in the world, with approximately $200 million in advisory revenues, approximately 370 staff, 300 of whom are experienced M&A bankers and growth company experts, offices in 14 locations in 10 countries around the globe, and more than 315 completed transactions over the last three years.
The combination brings together two extremely complementary businesses with a strong strategic and cultural fit. Together, GCA Savvian and Altium focus on growth companies and hold top positions in key growth sectors, particularly technology, digital media, telecommunications, eCommerce and retail. There are substantial opportunities for synergies between the two businesses, which will result in increased international reach to form outstanding cross-border capabilities and a truly global network in key markets. GCA will have offices in Tokyo, San Francisco, New York, Osaka, Shanghai, Singapore, Mumbai, London, Manchester, Frankfurt, Munich, Zurich, Milan and Tel Aviv.
“We are pleased to announce our merger with Altium. By bringing together these two established companies, we are creating a new global leader in our field,” said Aki Watanabe, Representative Director of GCA Savvian Corporation. “This combination will increase the scale and geographic reach of the firm – positioning GCA as the pre-eminent global investment bank focused on growth companies with a particular strength in technology.”
Phil Adams, CEO of Altium, said: “Our merger with GCA Savvian marks a key and exciting step in our growth strategy. Now, more than ever before, our clients are looking for integrated international coverage and this merger will enable us to provide the best possible service to our clients.”
The merger further increases the firm’s leading volume of cross border deals and will drive revenue growth while also further strengthening its presence within the private equity and venture capital community.
Both companies have built strong, reputable brands through their track records, highly experienced and respected management teams, independent, client-centric advice and transaction execution expertise.
GCA will continue to provide its clients with a broad range of investment banking services including M&A, capital markets, capital raising services for fund managers, debt advisory and private capital raising.
Under the terms of the agreement, which has been unanimously approved by the Boards of Directors of both GCA Savvian and Altium, Altium will merge 100% of its shares into GCA. GCA will be governed by a Board of Directors that includes, Geoffrey Baldwin, Todd Carter, Richard Kramlich, and Mark McInerney from the USA, Jiro Iwasaki, Isao Okubo, Hiroaki Ota, Masatake Yone, and Akihiro Watanabe (Representative Director) from Japan and Phil Adams, Alexander Grünwald and Sascha Pfeiffer from GCA Altium in Europe.
The transaction is subject to regulatory approval and other customary closing conditions and is expected to close early in the second half of 2016.
About GCA Savvian
GCA Savvian is a premier global investment bank serving growth companies through a range of services that include mergers and acquisitions, capital markets, private funds and restructuring advisory. GCA Savvian professionals deliver deep expertise in a range of industries such as technology, media & digital media, communications, healthcare, financial institutions, industrials, and e-commerce. The firm has offices in Tokyo, San Francisco, New York, London, Mumbai, Osaka, Shanghai, and Singapore.
Altium is a leading international mid-market financial advisory group, providing M&A, debt and corporate finance advice to companies, private equity firms and entrepreneurs. Established more than 30 years ago, Altium is a truly independent, employee-owned company. Today, the firm operates offices in London, Manchester, Frankfurt, Munich, Zurich, Milan and Tel Aviv. Altium has established itself as a global leader in mid-market private equity and debt advisory deals, as well as the Digital, Media & Internet, Technology & Telecom, Consumer & Retail, Healthcare, Industrials, Business Services and Energy sectors. Altium is dedicated to finding the best possible tailored solutions for its clients through its vast network, profound expertise, service and solution-oriented approach, and independent perspective.
James M. Kadleck, 415-318-3681
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Emmaus Life Sciences Announces the New England Journal of Medicine has Published the Phase 3 Trial Results of Endari™ (L-Glutamine Oral Powder) in Sickle Cell Disease18.7.2018 21:45 | Pressemelding
VIEW E-MEDIA KIT – Emmaus Life Sciences, Inc. (Emmaus) announced today that the New England Journal of Medicine (NEJM) has published the results of its 48-week phase 3 clinical trial of Endari™ (L-glutamine oral powder) which supported the FDA approval in July 2017 to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. The article reports results that showed significantly fewer sickle cell crises in those receiving Endari compared to placebo by 25 percent; p=0.005 (median 3 vs. median 4) and significantly fewer hospitalizations by 33 percent; p=0.005 (median 2 vs. median 3). Additional findings showed lower cumulative days in hospital of 41 percent; p=0.02 (median 6.5 days vs. median 11 days) and a lower incidence of acute chest syndrome (ACS) by more than 60 percent; p=0.003 (13 of 152 patients [8.6%] had at least 1 ACS compared with 18 of 78 in the placebo group [23.1%]). The most common adverse reactions, occurring in great
Tigo Releases State-of-the-art Wireless Technology – Mesh – as the New Solar Communication Architecture for the TS4 Platform18.7.2018 19:41 | Pressemelding
Tigo®, pioneer of the smart modular Flex MLPE platform, today announced the release of its new Mesh communication architecture. This state-of-the-art wireless technology directly translates to customer benefits – including simplifying the solar design process and accelerating the commissioning steps. The complete Tigo solution uses a simple yet powerful data collection technology that covers the widest ranges of residential & commercial installations at the lowest cost. With Mesh and the recently announced Tigo Access Point (TAP), customers eliminate the need to address any roof obstruction or orientation constraint. To learn more about Mesh and TAP, register for Tigo’s free, online webinar “The Future of Solar is Wireless” on Wednesday July 25th, 2018 at 10am PDT. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180718005827/en/ Mesh is Tigo's proprietary software that allows each TS4 unit to act as a repeater, extending the
ViiV Healthcare Shares Data from Landmark 2-Drug Regimen Trials At AIDS 201818.7.2018 17:21 | Pressemelding
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands. The data being presented this year has a strong focus on novel exploratory therapeutic options and innovative treatment strategies, as well as improving awareness and understanding of key issues that continue to affect the HIV community. John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “As we see advancements in the treatment options available to people living with HIV, our research efforts over the past few years have been focused on moving beyond viral load and addressing some of the unresolved issues that people living with HIV face, such as the potential long-term risks and toxicities that can be associated with li
Xilam: H1 2018 Revenue: +50%18.7.2018 16:00 | Pressemelding
Regulatory News: The Xilam Group (Paris:XIL) posted consolidated H1 2018 revenue of EUR 13,866 thousand, an increase of 50%. This increase represents an excellent performance, as it follows on the heels of growth of 54% in H1 2017. Revenue for the first part of this financial year breaks down as follows. In thousands of euros 30.06.2018 (1) 30.06.2017 Change New productions 8,465 4,571 +85% Catalogue 5,385 4,652 +16% Other 16 16 +0% Revenue and subsidies 13,866 9,239 +50% (1) Unaudited data. Remarkable success for new releases +85% Excellent H1 growth was driven by the two main businesses, New Productions and Catalogue. In New Productions, H1 deliveries generated record revenue of EUR 8,465 thousand, an 85% increase compared with H1 2017, and confirmed Xilam’s position as a major European animation company. Catalogue revenue was up 16% compared with H1 2017, thanks again to traditional TV channels and digital platforms, in both France and abroad. A fast-paced delivery schedule Thanks t
Department for International Trade: Life Sciences at the Heart of UK Economy18.7.2018 12:38 | Pressemelding
The Government will today (Wednesday 18 July) host the second in a series of roundtables with stakeholders from key life science businesses, demonstrating the importance of the sector to the UK economy. The Chancellor, International Trade Secretary, Business Secretary and Health and Social Care Secretary will be amongst those that meet with senior representatives from leading UK and international life sciences companies as the UK positions itself as the global home of health innovation, welcoming overseas investment and seeking to boost exports in the process. Discussions at the roundtable will focus on how the future of the Life Sciences sector will be supported by the delivery of our modern Industrial Strategy, ensuring that the UK is ‘open for business’ with a positive business environment, our ambitions for a comprehensive agreement with the EU on our future relationship and the development and implementation of our independent trade policy. To date, the government has engaged sign
Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials18.7.2018 12:05 | Pressemelding
Universal Laser Systems (ULS) announces the addition of 3M™, Victrex® and Dexmet materials to its materials database, the most extensive repository of laser material processing parameters for materials in the range of 10 watts to 500 watts. The 3M, Victrex and Dexmet materials new to the ULS materials database were specifically added for laser processing with the ULTRA and XLS platforms, suited for high accuracy and precision laser cutting, laser ablation and laser surface modification. The materials include: 3M™ Extreme Sealing Tape 4412N 3M™ Thermally Conductive Silicone Interface Pad 5516 Victrex® APTIV® PEEK Film Dexmet PolyGrid® 8PTFE10-125ST Expanded PTFE Dexmet MicroGrid® AL 25 Expanded Aluminum Laser processing notes, describing the results of the laser-material interaction for these materials, are also available in the Materials Library on the ULS website to help potential customers explore the advantages of deploying laser technology within their manufacturing, research and d